采用文献检索方法对动脉粥样硬化闭塞性疾病的基因治疗价值进行分析并加以综述。可选择的主要基因为促进血管再生和改善脂质代谢障碍的基因 ;转基因载体包括病毒性和非病毒性 ;转基因技术包括体外和体内转基因 ,后者包括开放外科、经皮注射和导管技术。血管再生可能导致的肿瘤生长和载体引起的危害是潜在的并发症。动脉粥样硬化闭塞性疾病的基因治疗有良好的前景 ,但动脉粥样硬化闭塞性疾病的特征性、发病机制还有待深入研究 ,载体和转基因技术还有待发展以提高安全性和效率。 The value of gene therapy for atherosclerotic occlusive disease was analyzed and reviewed by literature search. The major genes of choice are genes that promote angiogenesis and improve dyslipidemia; transgenic vectors include viral and non-viral; transgenic technologies include both in vitro and in vivo transgenes, the latter including open surgery, percutaneous injection, and catheterization techniques. Tumor growth and carrier-induced harm that may result from revascularization are potential complications. Gene therapy of atherosclerotic occlusive disease has a good prospect, but the characteristic and pathogenesis of atherosclerotic occlusive disease remains to be further studied. Vector and transgenic technology have yet to be developed to improve safety and efficiency.